Skip to content
The Peptide Effect
Comparison

Semaglutide vs Survodutide

Semaglutide (Wegovy/Ozempic) and survodutide (Boehringer Ingelheim's BI 456906) represent single vs. dual incretin agonist approaches to obesity and metabolic disease. Semaglutide, a pure GLP-1 receptor agonist, is the current gold standard with ~15% weight loss and robust cardiovascular outcomes data (SELECT trial). Survodutide is a dual GLP-1/glucagon receptor agonist in Phase 3 trials showing ~19% weight loss with particularly promising data for liver fat reduction in MASH (metabolic dysfunction-associated steatohepatitis). While semaglutide dominates the current market, survodutide's glucagon component may offer a differentiated profile for patients with fatty liver disease.

Side-by-side comparison diagram of Semaglutide and Survodutide mechanisms of action
Conceptual comparison — not to scale

Head-to-Head Comparison

CriteriaSemaglutideSurvodutide
Primary mechanismSelective GLP-1 receptor agonistDual GLP-1 + glucagon receptor agonist
Average weight loss~15–17% body weight at 68 weeks (2.4 mg Wegovy, STEP trials)~19% body weight at 46 weeks (Phase 2 data, highest dose)
FDA approval statusFDA-approved: Ozempic (2017, T2D), Wegovy (2021, obesity), Rybelsus (2019, oral)Phase 3 clinical trials (Boehringer Ingelheim); not yet approved
Injection frequencyOnce weekly (subcutaneous)Once weekly (subcutaneous)
Glucagon receptor activationNoneYes — increases energy expenditure, promotes hepatic fat oxidation
Liver fat reduction (MASH/MASLD)Moderate — secondary to weight loss; some direct hepatic GLP-1 effectsSubstantial — glucagon-driven hepatic fat oxidation; up to 87% relative reduction in liver fat in Phase 2
MASH fibrosis improvementLimited direct evidence for fibrosis reversalPhase 2 showed MASH resolution in 83% of patients and fibrosis improvement in 52%
Cardiovascular outcomes dataSELECT trial: 20% reduction in MACE in overweight/obese adults without diabetesNo completed cardiovascular outcomes trial
GI side effectsNausea (44%), diarrhea (30%), vomiting (24%) — well-characterizedNausea, diarrhea, vomiting at similar rates; potential for transient hyperglycemia during titration
Oral formulation availableYes — Rybelsus (oral semaglutide, lower efficacy than injectable)No — injectable only in current development
Effect on energy expenditureMinimal direct effect — weight loss primarily from appetite suppressionIncreased resting energy expenditure via glucagon receptor activation (thermogenesis)
Approximate monthly cost$1,350/month (Wegovy list price); $200–$500 compoundedNot commercially available yet

When to Choose Each

Choose Semaglutide

Proven weight loss therapy now, cardiovascular risk reduction (SELECT trial), patients wanting oral option (Rybelsus), established safety profile, insurance coverage

Choose Survodutide

MASH/MASLD with significant liver fat, patients seeking maximum weight loss, those who need enhanced energy expenditure, patients who failed or plateaued on GLP-1 monotherapy

Verdict

Semaglutide is the proven, available standard with strong cardiovascular outcomes data, multiple formulations (injectable and oral), and years of real-world safety evidence. It remains the first-line choice for most patients seeking pharmacological weight management today. Survodutide is the more compelling option specifically for patients with concurrent MASH/fatty liver disease, where the glucagon receptor component drives dramatic liver fat reduction beyond what GLP-1 alone achieves. If survodutide's Phase 3 results confirm the Phase 2 data, it could carve out a significant niche — or even challenge semaglutide broadly — particularly as liver disease becomes a larger focus of metabolic medicine.

References

  1. Survodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist, in overweight or obesity: SYNCHRONIZE-1 Phase 2 results (2024) — PubMed
  2. Once-weekly semaglutide in adults with overweight or obesity (STEP 1) (2021) — PubMed
  3. Semaglutide and cardiovascular outcomes in patients with overweight or obesity (SELECT trial) (2023) — PubMed
  4. Survodutide for the treatment of MASH and liver fibrosis: a Phase 2 randomised trial (2024) — PubMed
  5. Glucagon receptor agonism enhances the metabolic benefits of GLP-1 receptor agonism: a review (2022) — PubMed

Frequently Asked Questions

What advantage does survodutide have over semaglutide for liver disease?
Survodutide's glucagon receptor activation directly promotes hepatic fat oxidation — the liver breaks down its own stored fat. In Phase 2 trials for MASH, survodutide achieved MASH resolution (disappearance of the disease) in 83% of patients and fibrosis improvement in 52%, with an 87% relative reduction in liver fat content. Semaglutide reduces liver fat primarily as a downstream consequence of weight loss and has more modest direct hepatic effects. For patients with significant fatty liver disease, this glucagon-mediated mechanism is a major differentiator.
Does the glucagon component in survodutide cause blood sugar problems?
Glucagon naturally raises blood glucose by promoting hepatic glucose output, which seems counterproductive in a metabolic drug. However, survodutide's GLP-1 component stimulates insulin secretion and suppresses glucagon's glycemic effect sufficiently to maintain glucose control. In Phase 2 trials, survodutide actually improved HbA1c in patients with type 2 diabetes. Some transient hyperglycemia may occur during initial titration before the GLP-1 effect fully engages, which is managed through slow dose escalation.
Why not just use semaglutide since it is already available?
Semaglutide is an excellent choice and the pragmatic decision for most patients today. However, survodutide may offer advantages for specific populations: patients with MASH who need direct liver fat reduction, patients who plateau at ~15% weight loss on semaglutide and want more, and patients who would benefit from increased energy expenditure rather than appetite suppression alone. The dual mechanism is not just "more of the same" — the glucagon component adds qualitatively different metabolic effects that GLP-1 alone cannot provide.
When might survodutide become available?
Survodutide is in Phase 3 trials for both obesity and MASH as of 2025, sponsored by Boehringer Ingelheim in partnership with Zealand Pharma. Depending on trial results and regulatory review timelines, the earliest possible approval is estimated for late 2026 or 2027. Boehringer Ingelheim may seek approval for MASH first, as survodutide could be a first-in-class treatment for that indication, potentially accelerating review.
How does survodutide differ from tirzepatide and retatrutide?
All three are next-generation incretin-based therapies, but they target different receptor combinations. Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP agonist. Survodutide is a dual GLP-1/glucagon agonist. Retatrutide is a triple GLP-1/GIP/glucagon agonist. The key distinction is which additional receptor is activated beyond GLP-1: GIP primarily enhances insulin signaling and satiety, while glucagon increases energy expenditure and promotes liver fat oxidation. Survodutide and retatrutide both include glucagon, making them potentially more effective for fatty liver disease. Retatrutide covers all three receptors but remains further from approval. Consulting a healthcare provider about the evolving landscape of incretin therapies is recommended.

Explore next